Business Context and Reporting Period
Company: Novo Nordisk A/S, a global healthcare company headquartered in Denmark focused on diabetes and chronic diseases.
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Date: May 18, 2026.
Subject: Update on the company's share repurchase programme initiated on May 6, 2026, under the EU Market Abuse Regulation (MAR) "Safe Harbour" rules.
Key Financial Metrics and Capital Allocation
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow are not reported in this document).
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme Initiated May 6, 2026: Up to DKK 11,200,000,010.45 for B shares (May 6, 2026 – February 1, 2027).
- Cumulative Repurchases (Feb 4 – May 13, 2026): 15,999,028 B shares.
- Cumulative Transaction Value (Feb 4 – May 13, 2026): DKK 4,169,728,617.
- Average Share Price (Feb 4 – May 13, 2026): DKK 260.62 per B share.
- Treasury Shares Held: 33,184,329 B shares (0.7% of total share capital).
Material Changes and Recent Activity
The filing details specific transactions executed under the Safe Harbour programme between May 6 and May 13, 2026:
| Date | Shares Repurchased | Avg. Price (DKK) | Value (DKK) |
|---|---|---|---|
| May 6, 2026 | 199,849 | 300.66 | 60,086,659 |
| May 7, 2026 | 200,000 | 294.37 | 58,873,625 |
| May 8, 2026 | 210,000 | 290.45 | 60,993,987 |
| May 11, 2026 | 210,000 | 300.49 | 63,103,075 |
| May 12, 2026 | 210,000 | 300.81 | 63,169,735 |
| May 13, 2026 | 210,000 | 302.39 | 63,501,546 |
| Total (May 6-13) | 1,239,849 | - | 369,728,627 |
Note: An additional 204,498 shares were transferred net due to incentive programmes during this period; these were not part of the Safe Harbour repurchase programme.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period starting February 4, 2026.
Risks and Contingencies: The filing does not disclose new operational risks, contingencies, or unusual items. It strictly reports on compliance with the EU Market Abuse Regulation regarding share buybacks.
Management Commentary: The filing reiterates the company's purpose to defeat serious chronic diseases and notes its global footprint (approx. 67,900 employees in 80 countries).
Key Facts for Investor Verification
- Verify the remaining capacity of the DKK 15 billion repurchase programme (approx. DKK 10.83 billion remaining as of May 13, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 260.62 (Feb-May) and DKK 300+ (May 6-13).
- Monitor the total treasury share count, which now stands at 0.7% of the 4.465 billion total share capital.
- Check subsequent filings for updates on the execution of the programme through the February 1, 2027 deadline.